Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The AGNES case-control set consists of individuals with a first acute ST-elevation myocardial infarction. AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction. AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation. All cases and controls are recruited at seven heart centers in The Netherlands. The investigators' exclude individuals with an actual non-ST-elevation myocardial infarction, prior myocardial infarction, congenital heart defects, known structural heart disease, severe comorbidity, electrolyte disturbances, trauma at presentation, recent surgery, previous coronary artery bypass graft or use of class I and III antiarrhythmic drugs. Individuals who develop ventricular fibrillation during or after percutaneous coronary intervention are not eligible. Furthermore, because early reperfusion limits the opportunity of developing ventricular fibrillation, potential control subjects undergoing percutaneous coronary intervention within 2 h after onset of myocardial ischemia symptoms were not included. This time interval is based on the observation that >90% of cases develop ventricular fibrillation within 2 h after onset of the complaint of symptoms.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AGNES Controls | AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation. | ||
| AGNES cases | AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Differences in genetic and inflammatory profile between cases and controls. | Differences in genetic profile and inflammatory profile between cases and controls are investigated between the complete cohorts. | Immediately upon admission, measures are based on samples taken at admission. |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in clinical characteristics between cases and controls | Differences in clinical characteristics between cases and controls are investigated between the complete cohorts. | Immediately upon admission, measures are based on status at hospital admission. |
| Measure | Description | Time Frame |
|---|---|---|
| Previously described risk factors | Clinical characteristics that were previously described as possible risk factors for the development of VF (ventricular Fibrillation) during AMI (acute myocardial infarction): certain ECG characteristics, infarct size, infarct location, extent and localization of coronary disease. Are investigated for differences between cases and controls in the complete cohorts | Immediately upon admission, measures are based on status at hospital admission. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Cases are patients with a first ST-elevation myocardial infarction (STEMI) referred for primary percutaneous intervention (PCI), who develop ventricular fibrillation between the onset of acute myocardial infarction (chest pain, ECG changes) and reperfusion. Reperfusion can either be spontaneous or by PCI.
Control patients are patients with a first STEMI, referred for PCI who do not develop ventricular fibrillation.
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21461030 | Background | Marsman RF, Wilde AA, Bezzina CR. Genetic predisposition for sudden cardiac death in myocardial ischaemia: the Arrhythmia Genetics in the NEtherlandS study. Neth Heart J. 2011 Feb;19(2):96-100. doi: 10.1007/s12471-010-0070-4. Epub 2011 Jan 28. | |
| 20622880 | Result | Bezzina CR, Pazoki R, Bardai A, Marsman RF, de Jong JSSG, Blom MT, Scicluna BP, Jukema JW, Bindraban NR, Lichtner P, Pfeufer A, Bishopric NH, Roden DM, Meitinger T, Chugh SS, Myerburg RJ, Jouven X, Kaab S, Dekker LRC, Tan HL, Tanck MWT, Wilde AAM. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet. 2010 Aug;42(8):688-691. doi: 10.1038/ng.623. Epub 2010 Jul 11. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014693 | Ventricular Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA from blood.
| 29296283 | Derived | Gho JMIH, Postema PG, Conijn M, Bruinsma N, de Jong JSSG, Bezzina CR, Wilde AAM, Asselbergs FW. Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. Open Heart. 2017 Dec 22;4(2):e000551. doi: 10.1136/openhrt-2016-000551. eCollection 2017. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |